In MEF2C+ AML, SIK inhibitors seem highly effective and represent a rare example of kinase inhibitors that indirectly inactivate this oncogenic MEF2C transcription factor (39, 40, 48). The gene discussed is MEF2C; the disease is acute myeloid leukemia.